Pneumococcal vaccine impacts on the population genomics of non-typeable Haemophilus influenzae

David Cleary(University of Birmingham), Stuart C. Clarke(University Hospital Southampton NHS Foundation Trust), Rebecca A. Gladstone(Wellcome Sanger Institute), Denise E. Morris(University Hospital Southampton NHS Foundation Trust), Karen L. Osman(Defence Science and Technology Laboratory), Saul N. Faust(University Hospital Southampton NHS Foundation Trust), Stephen D. Bentley(Wellcome Sanger Institute), Vanessa T. Devine(University of Southampton)
Microbial Genomics
August 6, 2018
10.1099/mgen.0.000209
Cited by 21

Related Papers

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
|The Lancet|2020|5k
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18
|Nature|2001|1.3k
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
|The Lancet|2021|1.2k
Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children
|Pediatric Critical Care Medicine|2020|1.2k